

Approaches for valuing health impacts

Measuring the Impact of Voluntary Consensus Standards on Human Health and Safety

Chris Dockins*

National Center for Environmental Economics

US EPA




The opinions expressed in this presentation are mine and do not necessarily represent those of the EPA or federal government.

A graphic for World Standards Week featuring the text "World Standards Week" in a large, white, serif font. The text is overlaid on a background of vibrant, multi-colored brushstrokes in shades of blue, purple, green, and pink, creating a dynamic and artistic effect.

World
Standards
Week

Valuing health effects for benefits analysis



Economic analysis requires us

- quantify the changes in risk (or expected cases)
- estimate the economic value of those changes in risk

There are well-established valuation methods for providing two types of values

- willingness-to-pay
- cost-of-illness

EPA health effects for benefits analysis

Human Health Improvements	Methods
<p>Mortality risk reductions</p> <p><i>Reduced risk of premature mortality from an array of causes</i></p> <ul style="list-style-type: none">• acute fatality• cancer fatality	<ul style="list-style-type: none">• averting behaviors• hedonics• stated preference
<p>Morbidity risk reductions</p> <p><i>Reduced risk of other (non-fatal) health outcomes</i></p> <ul style="list-style-type: none">• non-fatal cancer• asthma• IQ changes• cardiovascular health• gastrointestinal illness• hospitalization• work loss days	<ul style="list-style-type: none">• averting behaviors• cost of illness• hedonics• stated preference

Valuing health risks with willingness to pay (WTP)

WTP is the appropriate measure of value in benefit-cost analysis.


What are affected people willing to pay to reduce their risk of an adverse health outcome (mortality or morbidity)?

Premature mortality


- *WTP for (relatively small) reduced risk of premature mortality*
- *Usually expressed as **Value of Statistical Life (VSL)***

Morbidity


- *WTP for (relatively small) reduced risk of non-fatal health outcome*
- *Usually expressed as value of a statistical case avoided*




The Value of Statistical Life (VSL)



In a population of 10,000, reducing pollution would avoid one premature death (i.e. reduce risk by 1/10,000)



Each of 10,000 are willing to pay \$900 to reduce risk of death by 1/10,000



WTP per unit of risk reduction is \$900 per 1/10,000, or \$9m per statistical life

This is the **Value of a Statistical Life (VSL)** Saved

Where do WTP values come from?

Market prices?

But we don't observe prices directly for "health" or "health risks"

Must use other methods to infer willingness to pay for risk reductions.




AHT TUNA STEAK	\$16.25 LB	CRAB MEAT RED	\$25.00 LB
BRAZILIAN WHOLE	\$9.90	CRAB MEAT DUNGENESS	
CALAMARI STEAKS	\$7.50 LB	FISH BONES	\$2.75 LB
CALAMARI T&T	\$5.50 LB	FLOUNDER WHOLE	\$3.90 LB
CLAMS LIVE	\$6.50 LB	FLOUNDER FILLET	\$9.50 LB
BROWN or VERMILLION ROCK COD WHOLE	\$8.50 LB	HALIBUT WHOLE	\$16.00 LB
CRAB LIVE	\$7.50 LB	HALIBUT STEAK	\$23.00 LB
CRAB COOKED	\$8.50 LB	HALIBUT FILLET	\$25.00 LB
COOK YOUR CRAB COOK, CLEAN, CRACK	\$2.00 EA \$3.00 EA	MUSSELS	\$6.00 LB

Where do WTP values come from?

Market prices

Related Markets (Revealed Preference)

- ***Averting (or defensive) behaviors*** where consumers make risk-income tradeoffs through goods they buy
 - *Safety equipment*
 - *Products that vary in actual/perceived safety (e.g., types of automobiles, bottled water)*




Where do WTP values come from?

Market prices

Related Markets (Revealed Preference)

- *Averting or defensive behaviors*
- **Hedonic wage (or wage-risk) studies** where workers accept higher risks if they receive a higher wage

*Widely used for
value of statistical life (VSL)
estimates*



Where do WTP values come from?

Market prices

Related Markets (Revealed Preference)

- *Defensive or averting behaviors*
- *Hedonic wage (or wage-risk) studies*

Hypothetical Markets (Stated Preference)

- *Survey method where people are asked about choices trading off risk for income*
- *Must be done carefully and rigorously*
- *The scenario can be tailored to the health effects and situation of interest*

Chance of getting cancer over 5 years

25 in 1 000

20 in 1 000

Chance of 5-year survival (if you get cancer)

60 %

70 %

Effects on everyday activities (if you get cancer)

Unable to work

Unable to work

Pain (if you get cancer)

Mild pain

Mild pain

Annual cost for each of the next 5 years (total in parentheses)

£ 0
(in total £ 0)

£ 210
(in total
£ 1050)

Which would you choose?

The current situation

Option A
(reduced risks)

Valuing health risks with Cost of Illness (COI)

COI a more limited measure than WTP but is often more readily available.

“Second-best” – underestimate of WTP


Medical (or “direct”) Costs

Expenditures on hospitalization, outpatient care, tests, etc.

Lost productivity (or “indirect”) Costs

Lost value of paid work time from absence or reduced productivity

Lost leisure time (often not included)



Applying health valuation estimates in BCA

Valuation estimates often need to be adapted (**benefit transfer**)

- differing populations, severity, timing

Premature mortality (*Value of Statistical Life*)


- Most agencies have clear guidance on what VSL to use (EPA ~\$10m)

Morbidity

- Relatively few willingness to pay estimates
- Illnesses vary in duration, severity, frequency, and impact on health

WTP and COI may be additive under some conditions

Types of values used in benefit-cost analysis



Valued using Willingness to Pay

- Premature mortality (VSL)
- Chronic Bronchitis
- Upper & Lower Respiratory Symptoms
- Asthma Exacerbation
- Minor Restricted Activity Days
- Acute Bronchitis

Valued using Cost of Illness

- Non-fatal myocardial infarction
- Hospital Admissions
- ER visits for asthma
- Work loss days & School loss days

Thank You!

Please feel free to contact me if you have with any questions

Chris Dockins

dockins.chris@epa.gov / 202-566-2286

National Center for Environmental Economics

US EPA

(www.epa.gov/economics)

References

Ščasný, Milan and A Alberini (2018) “The benefits of avoiding cancer (or dying from cancer): Evidence from a four-country study.” *Journal of Health Economics*, 57:249-262

US EPA (2011). *Cost and Benefits of the Clean Air Act*.

US EPA (2014). *Guidelines for Preparing Economic Analyses*.